38 results about "Adverse outcomes" patented technology

The invention provides an early death risk assessment model establishing method and device based on ensemble learning. The method and device are used for assessing the death risk of an old multi-organfailure patient during hospitalization based on diagnosis and treatment data of the first day when the old multi-organ failure patient enters an intensive care unit. The method comprises the steps ofdata set construction, data processing and model construction and evaluation. The method comprises the following steps: acquiring three pieces of demographic information, five pieces of vital sign information, five laboratory examination indexes and two clinical indexes of a patient on the first day during living in an intensive care unit; inputting the data into a risk assessment device, and carrying out internal data preprocessing, feature calculation and model operation. Finally, the risk of adverse outcomes in the hospital of the patient can be predicted early, and doctors are helped to treat the patient as soon as possible.

The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may, for example, be administered prior to transporting the patient to a health care facility, during transport of the patient to a health care facility, or in the emergency department. Further provided are methods of selecting individuals for such therapy. Further provided are methods of identifying individuals at increased risk of poor outcome following trauma. In certain embodiments the methods comprise determining whether the genotype of the patient includes an allele of a polymorphism in or near a complement-related gene, wherein said allele is associated with risk of poor outcome following trauma.

Systems, methods, and computer-readable media are provided for patient case and care complexity characterization, and detecting matches of an individual patient's record with collections of other patients' records, based on serial, longitudinal patterns, for facilitating efficient health services utilization, implementing programs to reduce complexity, preventive medicine, and risk management in health care. In an embodiment, time series are formed by electronically representing information pertaining to successive longitudinal episodes of health services utilization and the circumstances in which the episodes were incurred; calculating time-series K-nearest-neighbor clusters and distances for each combination; determining the cluster to which a given candidate patient complexity record is nearest, and prescribing one or more interventions specific to the plurality of hazards that are characteristic of trajectories that are members of that cluster, or that are deemed to be relevant to mitigating those hazards, thereby preventing the adverse outcomes and subsequent excess utilization that are prevalent in that cluster.

In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, treatment-specific prediction, or treatment selection, the methods comprising assessing the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor. In some aspects, the invention relates to the discovery that increased HSF1 expression and increased HSF1 activation correlate with poor outcome in cancer, e.g., breast cancer.

A quantitative measure of emergency department (“ED”) crowding and busyness is provided to ED staff and physicians substantially in real time. Further, the present invention enhances patient safety and improves quality of care by alerting ED personnel to of crowding, who are able to prevent adverse outcomes typically caused by ED crowding.

The current invention describes a method for selecting a particular population of women having a risk of developing obstetric or gynecologic pathologies indicated as odds ratio (OR) value higher than 5.5, comprising the following steps in order: a) determination of the levels of sialidase by means of the procedure described in Cauci et al. Am J Obstet Gynecol 1998; 178; 511-5 and/or prolidase activity by means of the procedure described in Cauci et al. J Infect Dis 1998; 178; 1698-706 in samples of body fluid; b) determination of the pH value of said body fluid samples; c) selecting the samples having a sialidase value equal or above 5.0 nmol of methoxyphenol and/or a prolidase level equal or above 1500 mOD for prolidase and a pH≧5.0. Consequently, this method gives the physician an efficient tool to decide whether or not to administer a pharmacological therapy to women at risk of severe adverse outcomes.

The invention relates to the field of artificial intelligence, and discloses a medication reminding method and related equipment based on time sequence clustering. The method comprises the following steps: acquiring medication compliance data of a sample user; clustering the medication compliance data to obtain a medication compliance mode; and reminding a target user according to a medication compliance mode of the target user. According to the invention, time sequence clustering is carried out on medication compliance data of a user to obtain a medication compliance mode, and a medication compliance classification model is obtained by combining basic information of a patient. The patient is reminded of medication according to the medication compliance classification model, then key medication of the patient can be reminded emphatically, and attention of the patient is improved while medication reminding cost is reduced, so that effectiveness of disease control is improved, and risksof complications and adverse outcomes are reduced.

A method of determining a therapeutic regimen in a patient with cancer comprising determining in a sample from the patient the tumor mutation burden (TMB) and loss of heterozygosity (LOH), wherein high TMB in combination with no LOH is indicative of a positive outcome when treated with a checkpoint inhibitor and high TMB with LOH is indicative of a poor outcome, is provided herein.

The invention discloses a Y-type joint pouring technology which is implemented by a primary pouring system and an auxiliary system, wherein the primary pouring system comprises a casting head, a feeding area, a feeding channel, a product wax pattern and a semi-closed space; a feeding sprue is formed in the top outer wall of the feeding area; the casting head is welded on the inner wall of the feeding sprue; the casting head and the feeding sprue are arranged at main hot spots of a casting by a step of arranging the feeding sprue and the casting head are the main hot spots of the casting according to the casting structure; continuous feeding is facilitated in a cooling process; through vertical pouring and under the pressure formed by the weight of molten steel, enough feeding ability is guaranteed for the part cooled earlier, based on a rule that thin walls are cooled earlier and the thick and big walls are supplemented. According to the technology disclosed by the invention, enough feeding ability is guaranteed for the part cooled earlier, thus, heat crack caused by stress concentration in molten steel cooling resulting from non-uniform wall thickness can be prevented, air holes and roughness caused by overheating as well as consequent adverse outcomes are avoided, and the requirements on the product performance are completely met.

The usage of compounds that improve fetal and neonatal outcome of preterm birth is described. These compounds are scavengers of ROS, their precursors, and agents that induce production of the scavengers. Examples of these compounds are glutathione, NAC, antioxidants, and spin trapping compounds. These compounds improve fetal outcome by inhibiting a fetal inflammatory process that may affect the fetus independently of prematurity. This fetal inflammatory response is characterized by increased cytokine and matrix metalloproteases (MMP) levels both in the mother and fetus and may be modulated by ROS at different levels. Targeting ROS formation with compounds such as specific antioxidants, glutathione or spin trapping compounds, their precursors, and/or agents which induce their production will suppress both the direct effects of ROS and its indirect effects through cytokines and MMPs already circulating in the system. This therapeutical intervention would limit the pathophysiologoical chain of events that ultimately leads to PPROM, preterm birth and/or adverse fetal and neonatal outcome.

This document provides methods and materials involved in assessing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials involved in assessing outcomes. For example, methods and materials for using the level of urinary CNP (e.g., a urinary to plasma CNP ratio) to determine whether or not a mammal is developing renal structural alterations (e.g., renal fibrosis, glomerular basement thickening, mesangial matrix expansion, swollen podocytes, and foot processes effacement) as well as methods and materials for using the level of urinary CNP levels to identify patients having an increased likelihood of experiencing a poor outcome are provided.